商品编号


AG-40T-0044-C005



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

5 ?g


商品信息


More Information



Product Details



Synonyms

Vascular Endothelial Growth Factor; VEGF-A; VPF



Product Type

Protein



Properties



Source/Host

Sf9 cells



Sequence

Mouse VEGF 164 (164aa).



Crossreactivity

Mouse



BIOLOG
ical Activity

The ED50 for stimulation of cell proliferation by human umbilical vein endothelial cells for VEGF 164 has been determined to be in the range of 1-5ng/ml.



MW

~48kDa



Purity

≥95% (SDS-PAGE)



Reconstitution

Reconstitute with 50mM acetic acid to a concentration not lower than 50μg/ml.



Formulation

Lyophilized.



Other Product Data

UniProt link Q00731: VEGF 164 (mouse)



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
For long term storage we recommend to add at least 0.1% human or bovine serum albumin.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Mouse vascular endothelial growth factor 164 (VEGF 164) is produced as a homodimer. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor
in vivo
. In addition to its action as a mitogen it is a potent vascular perme
ABI
lity factor (VPF)
in vivo
and is also a chemoattractant for monocytes and endothelial cells. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces perme
ABI
lization of blood vessels. It may play a role in increasing vascular perme
ABI
lity during lactation, when increased transport of molecules from the blood is required for efficient milk protein synthesis.


Product References
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis: F. Bock, et al.; Invest. Ophthalmol. Vis. Sci.
48
2545 (2007)